Parental Age and Risk of Infant Leukaemia: A Pooled Analysis

Erin L Marcotte1,2, Todd E Druley3, Kimberly J Johnson4

  • 1Division of Epidemiology & Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, MN.

Insights

Young paternal age increases the risk of infant acute lymphoblastic leukaemia (ALL). Older maternal age is linked to a higher risk of infant acute myeloid leukaemia (AML).

Area of Science:

  • Epidemiology
  • Pediatric Oncology
  • Genetics

Background:

  • Infant leukaemia (IL) is a rare childhood cancer with unknown causes.
  • De novo mutations are implicated in IL etiology.
  • Parental age is a known risk factor for adverse offspring outcomes, including cancers.

Purpose of the Study:

  • To investigate the association between parental age and infant leukaemia.
  • To analyze the risk of specific infant leukaemia subtypes (ALL, AML) in relation to maternal and paternal age.

Main Methods:

  • A case-control study analyzed registry data from 402 infant leukaemia cases and 45,392 controls.
  • Data from five US states (New York, Minnesota, California, Texas, Washington) for births between 1981-2004 were used.
  • Logistic regression calculated odds ratios (OR) and 95% confidence intervals (CI), adjusted for covariates.

Main Results:

  • Maternal age of 40 years or older was associated with an increased risk of infant acute myeloid leukaemia (AML) (OR 4.80).
  • Paternal age under 20 was associated with an increased risk of infant acute lymphoblastic leukaemia (ALL) (OR 3.69).

Conclusions:

  • Young paternal age is a risk factor for infant ALL.
  • Older maternal age is a risk factor for infant AML.
  • Further research should explore parent of origin effects, de novo mutations, and environmental exposures in IL etiology.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
356
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
353
Longitudinal Research02:20

Longitudinal Research

Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.5K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
274